Tiazofurin effects on IMP-dehydrogenase activity and expression in the leukemia cells of patients with CML blast crisis

Anticancer Research

Volumn 16, Issue 6 A, 1996, Pages 3349-3354

  Wright, Daniel G ^a   Boosalis, Michael S ^a   Waraska, Kristin ^a   Oshry, Lauren J ^a   Weintraub, Lewis R ^a   Vosburgh, Evan ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

IMP dehydrogenase; Myelogenous leukemia; Tiazofurin

Indexed keywords

GUANOSINE PHOSPHATE; MESSENGER RNA; OXIDOREDUCTASE; TIAZOFURIN;

ADULT; AGED; ARTICLE; BLAST CELL; BLAST CELL CRISIS; BLOOD CELL; BONE MARROW CELL; CASE REPORT; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DIARRHEA; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA CELL; LEUKEMIA REMISSION; LEUKOCYTE COUNT; MALAISE; MALE; MULTICENTER STUDY; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; BLAST CRISIS; FEMALE; HUMANS; IMP DEHYDROGENASE; LEUKEMIA, MYELOID, CHRONIC; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; MALE; MIDDLE AGED; RIBAVIRIN; RNA, MESSENGER;

EID: 0030499841     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Tricot GJ, Jarayam HN, Nichols CR, Pennington K, Lapis E, Weber G, and Huffman R: Hematologic and biochemical action of tiazofurin (NSC 286193) in a case of refractory acute myeloid leukemia. Cancer Res 47: 4988-4991, 1987.
2. Tricot GJ, Jarayam HN, Lapis E, Natsumeda Y, Nichols CR, Kneebone P, Heerema N, Weber G, and Hoffman R: Biochemically directed therapy of leukemia with tiazofurin, a selective blocker of inosie 5′-monophosphate dehydrogenase activity. Cancer Res 49: 3696-3701, 1989.
3. Lucas DL, Webster HK, and Wright DG: Purine metabolisms in myeloid precursor cells during maturation: Studies with the HL-60 cell line. J Clin Invest 72: 1889-1900, 1983.
4. Wright DG: A role for guanine ribonucleotides in the regulation of myeloid cell maturation. Blood 69: 334-338, 1987.
5. Glesne DA, Collart FR, and Huberman E: Regulation of IMP-dehydrogenase gene expression by its end products, guanine nucleotides. Mol Cell Biol 11: 5417-5422, 1991.
6. Tricot G, Jarayam HN, Weber G, Huffman R: Tiazofurin: Biological effects and uses. Int J Cell Cloning A: 161-170, 1940.
7. Knight RD, Mangum J, Lucas DL, Cooney DA, Khan EC, and Wright DG: Inosine monophosphate dehydrogenase and myeloid cell development. Blood 69: 634-639, 1987.
8. O'Dwyer PJ, Shoemacher DD, Jarayam HN, et al: Tiazofurin a new anti-tumor agent. Invest New Drugs 2: 79-84, 1984.
9. Balis FM, Lange BL, Packer RJ et al: Pediatric phase I trial and pharmacokinetics of tiazofurin (NSC 286193). Cancer Res 45: 5169-5172, 1985.
10. Roberts JD, Stewart JA, McCormack JJ el al: Phase I trial of tiazofurin administered by IV bolus daily for 5 days, with pharmacokinetic evaluation. Cancer Treat Rep 71: 141-149, 1987.
11. Dayton JS, Lindsten T, Thompson CB, and Mitchell BS: Effects of human T lymphocyte activation on inosinc monophosphate dehydrogenase expression. J Immunol 152: 984-990, 1994.
12. Nagai M, Natsumeda Y, and Weber G: Proliferation linked regulation of type II IMP-dehydrogenase gene in human normal lymphocytes and HL60 leukemic cells. Cancer Res 52: 258-265, 1992.